l of ry

e ia st
th nt du The 4th Annual
a sh ote in
e p a
nl et arm
U rk h
a p
o
ll m Bi
fu a’s
n di
I

27 – 29 November 2006, Hyatt Regency, Mumbai, India

Featuring key speakers
K K Tripathi
Advisor
Department of Biotechnology
Government of India, India

William J. Rutter
Co-founder, Director and
Chairman Emeritus
Chiron Corporation, USA

Ajaz Hussain
Vice President & Global Head
of Biopharmaceutical Development
Sandoz, USA

Saul Mashaal Flourish

CEO
Scigen, Australia - Singapore

Brian Tempest
Executive Vice Chairman
The Asia’s most significant and power-packed
Ranbaxy Laboratories, India biopharmaceutical event comes to India!

• A truly international platform for regulators, large pharmas, bio-tech

Subhash Kapre companies, investors, financiers, contract manufacturer s , legal & patent
President of R&D consultants and key stakeholders convene to do business
Serum Institute of India
• The first important event focusing strategic biopharmaceutical development
and manufacturing in India
Shrikumar Suryanarayan
President of R&D • 20+ CXOs from 10+ countries across 4 continents come together to explore
Biocon Limited, India
and discuss the latest trends, regulations, business models, partnership
opportunities, operational strategies and innovative technologies
Jean-Denis Shu
CEO and Chief Scientist
China Biopharma, China

Gold sponsor: Silver sponsor:

Separately bookable

Generic
Biopharmaceuticals Co-organiser: Organised by:
World Summit
Monday 27 November 2006

www.lifescienceworld.com/2006/bioasia
bioLOGIC Asia 2006 www.lifescienceworld.com/2006/bioasia

Flourish

India is THE hottest destination for biopharma!

India is one of the hottest biopharmaceutical spots in Our faculty of expert speakers includes:
Asia! The biotech industry is growing at 37% and bio- Dinesh Dua
pharma itself has surpassed US$1 billion sales in 2005- President, Biotechnology Strategic Business Unit
2006! India has: Wockhardt, India
• A huge market with a population of over one billion Hyi Jeong Ji
• Established domestic biopharmaceutical industry with Vice President of Biopharmaceutical Development
LG Life Sciences, Korea
highly skilled workforce
• Cost effective drug development and clinical trials (60% Nuggehally R. Srinivas
Executive Vice President, Drug Development
less than US average) with a diverse patient pool Dr Reddy’s Laboratories, India
• Extensive tax incentives and research funding from the Sandy Eisen
local government Chief Medical Officer
Teva Europe, UK
There is no better time to stage the bioLOGIC Asia 2006
in India than right now! This information-packed conference Varaprasad Reddy
Managing Director,
is a platform for international and Indian biopharma Shantha Biotechnics, India
industry leaders to explore the latest trends, regulation, Kee Long Hong
business models, outsourcing and partnership opportunities, Chairman & CEO
innovative technologies and best-in-breed operational Taiwan Liposome Company, Taiwan
strategies that work best for your industry. Arun Chandavarkar
Chief Operating Officer
This is definitely the right time to enter into the Indian Biocon Limited, India
biologic market and foster local partnerships! You need to Ravi Kiron
know: Executive Director
New Technology Assessment & Planning, Alza Corporation
• Is India the best location in Asia for investment Johnson & Johnson, USA
compared to other emerging markets like China? Chandra Viswanathan
• What are the opportunities and challenges your Vice President of Biologics
company will encounter and who shall your company Reliance Life Sciences, India
partner with locally? V A Srinivasan
• Should your company conduct clinical trials or Research Director
manufacturing in-house or through outsourcing? Indian Immunologicals, India
Steve Musgrave
You will find the answer at bioLOGIC Asia 2006. Vice President, Technical Operations, Biopharmaceutical
This is a must attend event for pharmaceutical and Centre of Excellence for Drug Discovery
biotechnology industry leaders as it provides the unique GlaxoSmithKline, UK
opportunity to network on an interactive level that
includes a line-up of world-class case study presentations,
Who should attend?
panel discussions and brainstorming of strategies.
• Biotech companies • Pharmaceutical
Why you must attend? • Bio-pharmaceutical companies
• International biopharmas – understanding the manufacturers • Biotechnology vendors
regulations, infrastructure, partnership opportunities • Government and • Life science servcice
and challenges in India biopharma industry regulators vendors
• Indian biopharmas – learning how to break into the • Biotechnology hub • Software and technical
international markets and look for local and • Legal consultants service vendors
international partners • Financing firms and • Logistics and supply
• Regional and international biotechs – understanding investment banks chain
the legal procedures to conduct clinical trials, R&D • Venture capital • CMO
and manufacturing in India, and forming new • Legal Consultants • CRO
partnerships • Technology consultants • Bioequipment vendors
• Indian biotechs – Expose to biopharmas and investors to • Construction and • Engineering /
promote and create greater awareness engineering vendors Construction vendors
• Biovendors – Meet, network and do business • Trade development
with biotechs and biopharmas from all over the world at Agencies
ONE location!

Register before 30 September 2006 and save up to US$350!

Reserve your seats today to enjoy our Early Bird offers!
Call us on +65 6322 2700 or register online via www.lifescienceworld.com/2006/bioasia
Monday 27 November 2006 www.lifescienceworld.com/2006/bioasia

Generic Biopharmaceuticals World Summit - Separately bookable

9.15 Chairman’s Opening Remarks • Critical technical issues to make biosililars equivalent and
available at cheaper price to reach the mass
OPPORTUNITIES AND CHALLENGES OF BIOSIMILAR DRUGS IN • Strategically view of sociopolictical influences of biosimilar
THE WORLD MARKET drugs
9.30 Biogenerics outlook – Opportunities and challenges of Dinesh Dua
biogenerics President, Biotechnology Strategic Business Unit
• Biosimilar drug industry development and market promises Wockhardt, India
• Overview of regulations for biosimilars to register and 3.00 Case study – Biocon’s experience in developing and
market in Europe and USA manufacturing biosimilars in India
• The story of Omnitrope – the first true biogeneric in the • Issues on developing and manufacturing Insulin and GCSF
European market • Key aspects on process development, facility design and
Ajaz Hussain formulation development
Vice President & Global Head of Biopharmaceutical • Strategies in characterization, comparability and clinical trials
Development Shrikumar Suryanarayan
Sandoz, USA President of R&D
10.10 Asia Pacific region – Launching platform for biosimilars in Biocon Limited, India
world markets: Development, manufacturing and business 3.40 From biogeneric to innovation – Shantha’s enterprise
development strategies journey
• Opportunities for biosimilars in Asia Pacific region • Supplying affordable biologics to the Mass: The story of
• Business development strategies for biosimilar products in Shanvac-B and Shanferon
the emerging markets – Racing against the regulatory clock • Shantha’s business model incorporating a balance between
• Strategies in overcoming European market entry barriers biosimilars and novel drug discoveries
with biosimilars manufactured in the Asia Pacific region • Future outlooks of world biogeneric market and strategic
Saul Mashaal development of Shantha
CEO Varaprasad Reddy
Scigen, Australia-Singapore Managing Director
10.50 Morning refreshments Shantha Biotechnics, India

11.20 Can biogenerics be equivalent? Critical issues in the 4.20 Afternoon refreshments
evaluation of biosimilar products 4.50 Panel discussion: Promise or challenge? The future of
• Regulatory approaches in the USA, Europe and other regions biogenerics and the role of Asia
• Pre-clinical immunoprofiling and comparision of biosimilars • Identifying the market trends and future opportunities for
• Considerations in conducting clinical trials for biosimilars biosimilar medicines
Sandy Eisen • Is biogeneric a threat or potential market for biopharmaceuticals?
Chief Medical Officer • A battle inevitable: How do branded biopharmaceuticals
TEVA Europe, UK compete with biogenerics after losing its patent?
12.00 East-West biogeneric alliance – The successful partnership • An over-saturation of biogenerics in the future market?
story between LG Life Sciences and biopartners in Moderator:
delivering Valtropin to the market K S Jayaraman
• Benefits and challenges in the East-West biogeneric India Correspondent
partnership Nature Publishing Group
• Evaluating criteria of a successful partnership model for Panelists:
biosimilar products Ajaz Hussain
• Lesson learnt and future outlook into biogeneric alliances Vice President and
Hyi Jeong Ji Global Head of Biopharmaceutical Development
Vice President of Biopharmaceutical Development Sandoz, USA
LG Life Sciences, Korea
Shrikumar Suryanarayan
12.40 China updates – The overview of biopharmaceutical President of R&D
market in China and its impact on neighboring Asian Biocon Limited, India
countries and the rest of the world
• China’s competency in the development and manufacturing Saul Mashaal
of biopharmaceuticals and biosimilars CEO
• Identifying key strategies for foreign biopharmaceutical Scigen, Australia-Singapore
manufacturers to break into China market
• Opportunities on future partnerships between India and Dinesh Dua
China in the competitive biogeneric industry President, Biotechnology Strategic Business Unit
Jean-Denis Shu Wockhardt, India
CEO Varaprasad Reddy
China Biopharma, China Managing Director
1.20 Networking Luncheon for delegates and speakers Shantha Biotechnics, India

DEVELOPING AND MANUFACTURING BIOSIMILAR DRUGS Hyi Jeong Ji

IN INDIA Vice President of Biopharmaceutical Development
LG Life Sciences, Korea
2.20 Biogenerics, biosimilars or follow on biologics – The
changing paradigm in regulatory and sociopolitical Sandy Eisen
perspective in non-regulated, semi-regulated & highly Chief Medical Officer
regulated markets Teva Europe, UK
• Understanding the concept and differences of the regulatory 5.50 Chairman’s Closing Remarks
mechanisms in the un-regulated, semi-regulated and highly
regulated markets 6.00 End of Generic Biopharmaceutical Summit
• Identifying the challenges in gaining market share and factors
in succeeding in these three markets
Day One Tuesday 28 November 2006 www.lifescienceworld.com/2006/bioasia

Flourish

9.00 Organiser’s welcome remarks Saul Mashaal

CEO
9.05 Co-organiser’s welcome remarks Scigen, Australia-Singapore
Mr Gautam Thapar
Chairman 11.00 Morning refreshments
CII National Committee on Biotechnology
and Chairman, Ballarpur Industries Ltd REGULATORY, POLICY AND INFRASTRUCTURE DEVELOPMENTS
IN INDIA
9.15 Chairperson’s opening remarks
11.30 National biotechnology development polices and
BIOPHARMA OPPORTUNITIES AND CHALLENGES IN INDIA strategies in India
• Updates on national policies, patent laws, licensing and
9.20 Competitive advantage of India for biophamaceutical pricing regulations and exportation guidelines for
development and manufacturing: What’s its role in the biopharma manufacturing in India
global context? • How drug discovery and product development can be
• Global biopharma industry ecology: Trends, current accelerated in India
developments and future prospects • Understanding bio-safety and ethical issues and their impact
• Advantages of India: Talent pool, regulations, on biopharma industry in India
infrastructure, logistics, facilities and IPR for pre-clinical • Government incentives and strategies for developing the
and clinical development and manufacturing bio industry
• Understanding key advantages and obstacles in K K Tripathi
fostering a biopharma partnership and setting up a Advisor, Department of Biotechnology
biopharma manufacturing plant in India Government of India, India
• Challenges for a multinational to enter and succeed in
the competitive marketplace 12.00 Panel discussion: Key insights into the private public
• Opportunity in developing India into a research and partnership (PPP) model in India and best practices in
manufacturing-to-export hub for biologic drugs other countries
William J. Rutter • Current PPP models in India: What are the pros and cons?
Co-founder, Director and Chairman Emeritus • What private sector looking for in a PPP in India?
Chiron Corporation, USA • Successful models in other countries: Can they be
implemented in India?
9.50 Understanding how Indian biopharmas are embracing • Moving forward: India government’s long-term plan to
international competition and establishing global develop PPP in the bio industry
presence Moderator:
• Factual analysis of what takes India to become the world’s N. K. Ganguly
leading biopharma hub Director
• An overview of the market trends and dynamics that are Indian Council of Medical Research, India
propelling growth in the Indian biopharma industry
• Evaluating successful business models and identifying Dr Krishna Mohan,
critical factors to success Representative,
• Identifying key challenges in exporting biopharma products CII, National Committee on Biotechnology
to the rest of the world and President, Bharat Biotech
Brian Tempest
Executive Vice Chairman Panelists:
Ranbaxy Laboratories, India K K Tripathi
Advisor, Department of Biotechnology
10.20 Panel discussion: Presenting business cases for Government of India, India
biopharma industry in India compared to other parts
of Asia Jean-Denis Shu
• Market opportunities, challenges and regulation comparison CEO
between India and China, Korea, Singapore, Malaysia, China Biopharma, China
and Vietnam Saul Mashaal
• A strategic evaluation of pros and cons in each countries on CEO
R&D, regulation and IP issues, clinical trials, manufacturing, Scigen, Australia-Singapore
talent, outsourcing capabilities, in-market sales potential
• Understanding culture differences and infrastructure Byung-Se Kwon
obstacles in different countries CEO
• Investing in new bio-tech start-ups: A comparison of biotech Immunomics, Korea
start-ups across different Asian countries and identifying
key criteria for investment 12.40 Luncheon for speakers and delegates
• Moving forward: How industry leaders assess the future of
India biopharma industry with respect to the rest of OPTIMISING YOUR BIOMANUFACTURING CAPABILITY AND
the world COMPETENCY IN INDIA
Moderator:
Ravi Kiron 1.40 Bioprocessing challenges and recent development
Executive Director in India
New Technology Assessment & Planning, Alza Corporation • Identifying India’s advantages in bioprocessing and
Johnson & Johnson, USA scale-up manufacturing: Natural resources, talent pool and
established facilities
Panelists: • Comparison of bioprocessing regulations between India
Brian Tempest and Europe, USA and other parts of Asia
Executive Vice Chairman • Overview of bioprocessing plants in India: Does it meet
Ranbaxy Laboratories, India with the global standards?
Jean-Denis Shu • Infrastructure concerns and solutions in setting up a
CEO bioprocessing plant in India
China Biopharma, China • Maximising efficiency and cost effectiveness in daily
operations
Rajesh Jain Arun Chandavarkar
Joint Managing Director Chief Operating Officer
Panacea Biotec, India Biocon Limited, India
Byung-Se Kwon 2.10 Smarter, faster, purer: Emerging technologies in
CEO downstream processing
Immunomics, Korea • Understanding biomanufacturing as a fixed-cost driven business
Day One (cont’d) www.lifescienceworld.com/2006/bioasia

Flourish

• Identifying current backlog in bioseparation technologies Krishna Mohan

• Renaissance of robust, efficient and scalable unit operations President
and manufacturing platforms Bharat Biotech
• Modern safety concepts for reliable removal of TSE, viruses
and process-derived contaminants Dr. Arnab Kapat
Dr Uwe Gottschalk Director, Reliance School of Life Sciences
Vice President Purification Technologies Dhirubhai Ambani Life Sciences Center
Sartorius AG, Germany
5.30 Panel discussion: Outsourcing biomanufacturing to India
2.40 Panel discussion: Regulatory and infrastructure – Critical issues when selecting a CMO and managing
considerations in setting up a biomanufacturing facility quality while outsourcing
in India • Understanding contract manufacturing capacity and
• Identifying the infrastructure challenges and regulatory capability in India
issues in setting up a plant in India • Exploring the opportunities for process development and
• Critical factors on choosing the location of your plant India: testing in India
Pros and cons of different locations • Identifying the competitive advantages and challenges of
• Understanding logistics issues in India and their impact on contract manufacturing of biologics in India
different business models • Criteria for selecting the best CMO partner
• Key strategies in overcoming regulatory and logistical challenges • How to negotiate and establish an appropriate service
Moderator: agreement with your outsourcing partner
Utkarsh Palnitkar • Methods of protecting your IP rights to prevent possible
Leader piracy
Business Advisory Services, Moderator:
Ernst and Young Scott M. Wheelwright
President
Panelists: Strategic Manufacturing Worldwide, USA
V A Srinivasan
Research Director Panelists:
Indian Immunologicals, India Steve Musgrave
Vice President Technical Operations
Sarma Duddu Biopharmaceutical Centre of Excellence for Drug Discovery
Director GlaxoSmithKline, UK
Nektar Therapeutics, USA
Hazel Aranha
Kasim A. Mookhtiar
RAC. President
Chief Scientific Officer and Senior Vice President
GAEA Resources Inc., USA
Advinus Therapeutics, India
6.10 Chairperson’s closing summary
3.20 Much like speed-dating, through a rotating
cocktail table format, you will get the
6.20 End of conference Day 1 and welcome networking cocktail
opportunity to meet all your fellow
party
attendees face-to-face in just 30 minutes. Bring plenty of
business cards along for a fast and furious interactive session.
At bioLOGIC Asia 2006, you will:
3.50 Afternoon refreshments

4.10 Case study: Your practical guide in achieving

biomanufacturing excellence in Asia
• Proven bioprocessing practices for monoclonal antibodies
and vaccines
• Regulatory and validation supporting practices to meet with
the FDA standard
• What can the wider GE family help in bioprocessing: Water,
infrastructure, operation system concerns to achieve the a
synergy in bioprocessing set-up
Peter Ehrenheim
President, Life Sciences
GE Healthcare, Sweden
Create partnerships and alliances
4.40 Panel discussion: Simplifying complex scale-up and
downstream processes
• Novel technology evaluation criteria and bioprocess
technology transfer for cost effective scale-up and
manufacturing
• Overcoming scale-up issues in downstream processing:
Novel approaches of downstream process design to
decrease timelines and cost
• Reality and Optimization: Implementing manufacturing
technology scale-up from lab to commercial scale
• Product Throughput and Viral Clearance
• Implementing manufacturing technology scale-up from lab
to commercial scale
Moderator:
John Curling Hear updates from industry leaders
Senior Scientist and Consultant
Prometic Biosciences, Sweden
Media Partners:
Panelists:
Joe Zhou
Principal Scientist, Purification Process Department
Amgen Inc., USA
Dr Uwe Gottschalk
Vice President Purification Technologies,
Sartorius AG, Germany
Day Two Wednesday 29 November 2006 www.lifescienceworld.com/2006/bioasia

Flourish

9.00 Chairperson’s opening remarks Moderator:

S K Gupta
INDIA SET TO BECOME THE HUB FOR INNOVATIVE Director
BIOPHARMA R&D: CURRENT BIOTECH R&D LANDSCAPE, Institute of Clinical Research, India
FINANCING OPPORTUNITIES AND FUTURE OUTLOOKS IN INDIA
Panelists:
9.15 Critical insights into biologic drug discovery and Dr Vinod Mattoo
development capabilities and challenges in India Chief Scientific Officer
• Overview of biopharma innovation, R&D resources and Eli Lilly, India
capabilities in India Sanjoy K Datta
• R&D incentives and support from the government and Director of Clinical R&D and Medical Affairs
IP issues GlaxoSmithKline, South Asia
• Novel strategies and business models to minimise cost and
accelerate drug discovery process Nuggehally R. Srinivas
• Determining the validation and quality assessment criteria Executive Vice President, Drug Development
for R&D Dr Reddy’s Laboratories, India
• The future prospect and discovery trends: What are the
diseases targets and therapeutic strategies 12.45 Luncheon for speakers and delegates
Subhash Kapre
President of R&D ASIAN INNOVATIVE BIOLOGIC DISCOVERY FORUM:
Serum Institute of India SHOWCASE OF INNOVATIVE BIOLOGIC DRUG/THERAPY
DISCOVERIES FROM PROMISING BIOTECHS AND R&D LEADERS
9.45 Advantages of conducting stem cell and tissue
engineering research in India and identifying its industry R&D is the most lengthy and costly step in modern drug discovery,
applications which is also the key for current biopharmas to sustain growth and
• Competitive advantages of regulatory systems and competitive advantage. This forum will bring together leading
resources in doing stem cell research in India biotech companies and R&D leaders from India and Asia to present their
• The gap between the research and industry latest discoveries to pharma giants and investors. It will be a unique
• Potential industrial applications of stem cell research: platform where R&D leaders, biotech firms, pharma companies and
Cell-based therapies and screening new drugs and toxins investors come together to discuss, evaluate and find out the most
• Critical concerns in setting up a global partnership in stem up-to-date innovative biologic drug candidates, delivery technologies
cell research in India and R&D capabilities across the region.
Chandra Viswanathan
Vice President of Biologics 2.00 Chairman’s opening remarks
Reliance Life Sciences, India
2.15 Novel therapeutic molecules and prophylactic vaccine
10.15 Big pharma’s perspective in establishing a successful R&D strategies against Staphylococcal infections
partnership in India Krishna Mohan
• Key insights into the current partnership models, President
deal-making trend, success and pitfalls in real cases Bharat Biotech
• Identifying key factors for big pharma to select a strategic
R&D partner in emerging markets 3.00 Inducible costimulation-targeted immunotherapy against
• Benchmarking methodologies for a successful partnership cancers and autoimmune diseases
and considerations and issues with regard to international Byoung S. Kwon
strategic alliances CEO
Ravi Kiron Immunomics, Korea
Executive Director for New Technology Assessment and
Planning, Alza Corporation 3.45 Development of targeted liposome drug delivery system
Johnson & Johnson, USA Kee Long Hong
Chairman & CEO
10.45 Morning refreshments Taiwan Liposome Company, Taiwan

INDIA AS A HOTBED FOR CLINICAL DRUG DEVELOPMENTS: 4.30 Harnessing the bodies’ own natural human immune
ADVANTAGES, ISSUES AND BEST PRACTICES response: A tool in the development of a specific human
monoclonal antibody against non small cell lung
11.30 Trends and opportunities for biopharma companies to carcinoma
conduct clinical trials in India Sonjoy Mukerjee
• Understanding the advantages of establishing clinical trials Head of Monoclonal Antibodies
in India Shantha Biotechnics, India
• Infrastructure, network and logistics issues: What can be
improved and what are the expectations from multinational 5.15 Question and answer session
companies
• Comparison of cultural and regulatory hurdles in clinical 5.30 Chairman’s closing remarks
development between India and other countries of Asia
Dr Vinod Mattoo 5.40 End of conference day 2
Chief Scientific Officer
Eli Lilly, India

12.00 Panel discussion: Strategies in conducting clinical trial in

India in the most cost effective and efficient way
• Clinical compliance guidelines and ethical issues for doing Early Bird discounts available!
clinical trials in India Register before 30 September 2006 and
• Challenges and solutions in patient recruitment,
partnerships, and safety and risk management save up to USD349.5!
• Approaches to be more efficient and cost effective in doing
clinical trials in India
Call +65 6322 2700 or visit
• Practical considerations for designing a successful clinical www.lifescienceworld.com/2006/bioasia
trial
to reserve your seats.
bioLOGIC Asia 2006 www.lifescienceworld.com/2006/bioasia

Flourish

Create an impact! Reinforce your market position and

meet India’s most qualified buyers at bioLOGIC Asia 2006
Would you like to position yourself as a Who should sponsor?
leading player in the burgeoning Indian Co-organised with the Confederation of Indian
biopharmaceutical industry? Industry, this event will provide an excellent opportunity
for service and solution providers to reach out to
Be our partner – be seen as prestigious sponsor at the 4th established biopharm and biotech key industry players
and those who are entering into this Asia’s fastest
annual bioLOGIC Asia 2006 – the perfect platform growing market. We are looking for the following profile of
to showcase your product, technologies, services and organizations to partner up with us at this event:
solutions.
• Pharmaceutical companies
Why you should sponsor? • Contract manufacturers
• Contract research organizations
Branding • Technology vendors
• Reagents and bio-consumables vendors
Establish your brand in Indian biopharmaceutical’s • Software and bioinformatics
best minds in just 3 days - Position and profile • Equipment providers
yourself as an industry leader with strategic sponsorship • Law firms
and exhibiting opportunities. • Consultants
• Venture capitalists and investment banks
Speaking opportunities • Logistics and supply chain management
Showcase your best technology and services by • Construction Companies
addressing an audience of top executives from India • Regional Development Agencies
biopharmaceutical industry! • Bioparks
About our sponsors
Highly targeted
Don’t you find some shows are too vendor focused? Gold sponsor:
The Sartorius Group is an intenationally
Not Ours! With a selective focus on profiles and leading laboratory and process technology
carefully targeted audience, bioLOGIC Asia 2006 is a supplier covering the segments of biotechnology and mechatronics. The
highly cost-effective sales and marketing platform. Goettingen-based company founded in 1870 currently employs a good
3,600 persons. Its biotechnology segment focuses on filtration and
Two-way communication process separation products, bioreactors and proteomics. The mechatronics
Shake hands and make friends with your Indian segment manufactures, in particular, equipment and systems, which
business partners! Conferences provide two-way feature weighing, measurement and automation technology for
communication with face-to-face contact – the most laboratory and industrial applications, as well as hydrodynamic bearings.
persuasive form of selling. Sartorius key customers are from the pharmaceutical, chemical and food
and beverage industries and from numerous research and educational
Fast market penetration institutes of the public sector.
It takes too long to travel to different bioclusters
Sartorius has its own production facilities in Europe, Asia and America as
in India? NO more hesitation, you can reach a large well as sales subsidiaries and local commercial agencies in more than 110
proportion of the market in just 3 days! The buyers come countries.
to you – bioLOGIC Asia is attended by biopharmaceutical
industry decision makers from India, other parts of Asia Silver sponsor:
and across the world. GE Healthcare provides life science r e s e a r c h
products and biopharmaceutical manufacturing
Return on Investment technologies. Over 90% of the current biopharmaceuticals therapies
Hard to find the RIGHT contacts? You can obtain on the market are manufactured utilizing chromatography media from
direct access to potential clients during and after the GE Healthcare. In addition, our service organization helps you improve
event with the meticulously prepared confidential productivity and reduce costs associated with the upkeep of laboratory
delegate lists. and manufacturing equipment.
Exhibitors:

Be a LEADER in your industry. Heighten your corporate profile by positioning yourself as

a KEY SPONSOR at bioLOGIC Asia 2006. For more information on our various sponsorship
packages, please contact Ms. Tingting Wang, Conference Manager Tel: +65 6322 2775 or
email tingting.wang@terrapinn.com
bioLOGIC Asia 2006 www.lifescienceworld.com/2006/bioasia
Registration form 4 easy ways to register

Phone: (65) 6322 2771

Fax: (65) 6223 3554
Website : www.lifescienceworld.com/2006/bioasia
Post: Terrapinn Pte Ltd
1 Harbourfront Place, #18-01,
Harbourfront Tower One, Singapore 098633
Biz Reg No: 198902388R
If you have any enquiries about the event, please contact
27 – 29 November 2006, Hyatt Regency, Mumbai, India kinsum.kong@terrapinn.com

Delegated fees

Package Dates Normal price Discounted price EARLY BIRD OFFER!

(register before 30 September 2006) Save up to
c Gold Pass (Conference & One day Summit) 27 - 29 Nov 2006 USD 3,495 USD 3,145.50 Save USD 349.50 USD 349.50 if you
c 2 day conference 28 - 29 Nov 2006 USD 2,295 USD 2,065.50 Save USD 229.50 register before
c Generic Biopharmaceuticals World Summit 27 Nov 2006 USD 1,695 USD 1,525.50 Save USD 169.50 30 September 2006!
* The registration fee includes luncheons, refreshments and full conference documentation. The fee does not include hotel accommodation. Payment terms are 7 days. Delegates may be refused
admission if payment is not received prior to the conference.

Coporate groups. Yes, I want to send a team and save even more.

Delegates Package Normal Price Group Price Save Benefits to corporate groups:
c 3 3 Day Gold pass USD 10,485 USD 9,436.50 USD 1,048.50 • Reserved seats at conference
c 6 3 Day Gold pass USD 20,970 USD 16,776 USD 4,194 • Priority check-in
c 8 3 Day Gold pass USD 27,960 USD 20,970 USD 6,990 • VIP registration packs
** Corporated booking prices cannot be used in conjunction with any other promotional prices

Attendees Details

Mr/Mrs/Ms Full Name Job Title Telephone Email

1
2
3

Company Details Venue and Hotel Accomadation

Signatory must be authorised to sign on behalf of contracting organisation Venue:
Name: Hyatt Regency Mumbai,
Sahar Airport Road,
Job title: Mumbai, India 400 099
Tel: 91 22 6696 1234 Fax: 91 22 6696 1235
Authorising Signature:
Email: india.reservations@hyattintl.com
Email:
Hotel accomodation: Special corporation rates have been negotiated
Organisation name: for conference delegates. Please make your bookings directly with
the hotel and indicate that you are attending Terrapinn’s bioLogic
Industry: Asia 2006
Address:

Postcode: Country: Data protection

Tel: Fax: Terrapinn (or it’s agents) may contact you by mail, phone or email about
products and services offered by Terrapinn and it’s group companies, which
Terrapinn beleives may be of interest to you, or about relevant products and services
Method of payment offered by reputable third parties. Terrapinn may also disclose your contact
Payment terms are 7 days. The conference registration pack will be sent to you once payment
details to such third parties to enable them to contact you directly. Certain
entities to which Terrapinn discloses your contact details are located in
has been received.
territories overseas whihc have fewer legal safeguards to protect personal
c Bank Transfer c Crossed cheque payable to Terrapinn Pte Ltd data. By returning this form to us, you agree to our processing of your personal
c Mastercard c Visa c American Express c JCB c Please invoice me information in this way. Please tick the appropriate box if you do not wish to
Payment via Visa & Mastercard will be converted and charged in USD at the prevailing rate in receive such information from: c the Terrapinn group; c or reputable third parties.
order to comply with the bank’s policy

Cardholder’s Name:
Cancellation and transfer
Card Number: Should you be unable to attend, a substitute is welcome at no extra charge.
Alternatively, you may choose to credit the full value of your registration
Cardholder’s Signature: towards a future Terrapinn event. A 50% refund and the course documentation
will be provided for cancellations receiving in writing 2 weeks in advance. The
Expiry Date: company regrets that no refunds will be made for cancellations received less than
2 weeks prior to the conference. A complete set of course documentation will,
Bank Transfers: Payment by bank transfer must quote the delegate name and reference however, be sent to you. Terrapinn reserves the right to cancel or alter the content and
below. Transfer should be made to Standard Chartered Bank, timing of the program or the identity of speakers for reasons beyond its control.
6 Battery Road, Sinagpore 049909
Account name: Terrapinn Pte Ltd, Account No. 01-741-0231-3
Payment must be received before the conference date in order to guarantee your place.
unpaid registrations will be billed 50% of the registration fee if you do not attend the For official use only
event. you will, however, be given access to our online contact system, and a copy of
the conference documentation will be sent to you. reference – 131209 Received: c Date: Code: 131209 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z